Cephalon options Alba's coeliac disease drug larazotide rejected by shire
This article was originally published in Scrip
Executive Summary
Cephalon has signed an option agreement to purchase all of Alba Therapeutics' assets related to its coeliac disease candidate larazotide acetate (AT-1001), which is an orally administered zonulin receptor antagonist progressing toward a redesigned Phase IIb trial.